Oryzon Genomics Announces Successful Shareholders Meeting
In a recent gathering held in Madrid, Oryzon Genomics S.A., a prominent player in the biopharmaceutical sector, proudly reported all the resolutions passed during the Extraordinary General Shareholders' Meeting. An impressive 37.8% of voting rights were either present or represented at this pivotal meeting, showcasing the active engagement of Oryzon’s shareholders.
The shareholders unanimously approved several significant resolutions presented by the Board of Directors, with favorable votes ranging from 93% to an astonishing 98%. These decisions are crucial as they set the stage for the company’s strategic direction and operational framework in the upcoming years.
Key Resolutions Approved
Several resolutions were on the table for approval, each of which carries considerable weight for the future operations of Oryzon. The key resolutions that garnered support include:
Amendments to Company Bylaws
Firstly, a technical amendment to Article 2 of the Company’s Bylaws was approved. This amendment modernizes the corporate purpose of Oryzon, aligning it with the New National Classification of Economic Activities (CNAE 2025).
Changes in Director Remuneration
Additionally, the Company’s Bylaws regarding the remuneration of its Board of Directors saw an important amendment. A new Remuneration Policy intended to span the next three financial years—2026, 2027, and 2028—was also approved. This policy is designed to attract skilled professionals to support Oryzon’s goals and mission.
Long-Term Incentive Plans
A Long-Term Incentive Plan covering the same three-year period was accepted for the company’s executives and key personnel, including the Executive Chairman. The move is part of Oryzon’s ongoing commitment to reward and retain talent within its ranks.
Capital Increase Authorization
Moreover, shareholders authorized a capital increase of up to €125 million. This increase will be facilitated through cash contributions with a notable exclusion of preemptive subscription rights. This decision empowers the Board of Directors to set specific terms for the issuance, a strategic move aligning with Article 505 of the Spanish Companies Act.
Empowering the Board with Delegated Powers
Lastly, the resolutions included a delegation of powers to ensure the proper formalization, registration, and execution of all decisions adopted during the General Shareholders' Meeting.
The complete details of these resolutions and the individual voting tallies are available on the official Oryzon website, ensuring transparency and accessibility for all shareholders.
About Oryzon Genomics
Founded in 2000, Oryzon Genomics stands as a beacon of innovation in the biopharmaceutical industry. Based in Barcelona, Spain, the company is recognized as a leader in the field of epigenetics, primarily focusing on personalized medicine targeting central nervous system (CNS) disorders and oncology. Oryzon’s highly skilled team is composed of seasoned professionals who are situated across key locations in Barcelona, Boston, and San Diego.
Oryzon's clinical portfolio is robust, featuring LSD1 inhibitors like vafidemstat, currently ready for Phase III trials in CNS applications, and iadademstat, which is in Phase II for oncology and hematology indications. The company also continues to develop other pipeline assets aimed at different epigenetic targets, including a clinical candidate, ORY-4001, which is under consideration for diseases such as Charcot-Marie-Tooth and Amyotrophic Lateral Sclerosis.
With a strong emphasis on biomarker identification and target validation, Oryzon remains committed to advancing treatments for various malignant and neurological diseases, further solidifying its position in the biopharmaceutical landscape.
Frequently Asked Questions
What were the results of the Oryzon Genomics shareholders' meeting?
All resolutions presented were approved with high favorable votes, demonstrating strong shareholder support.
What amendments were made to the Company's Bylaws?
Notable amendments included updates to corporate purpose and director remuneration policies to align with new standards.
What is the purpose of the Long-Term Incentive Plan?
The plan aims to retain key executives and align their goals with the company's long-term success.
How much capital increase was approved?
A capital increase of up to €125 million was authorized, enabling strategic investments for Oryzon's growth.
Where can I find more information about Oryzon Genomics?
More details can be found on Oryzon's official website, which offers insights into corporate activities and updates.
